CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations.


Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 10 2018
accepted: 10 12 2018
pubmed: 29 12 2018
medline: 24 12 2019
entrez: 29 12 2018
Statut: ppublish

Résumé

The main objective of this study was to develop and evaluate the CNS delivery efficiency, distribution, therapeutic efficacy, and safety of cyclosporine A (CSA) using a cationic oil-in-water nanoemulsion system upon intranasal administration. An omega-3 fatty acid-rich, flaxseed oil-based nanoemulsion was used for intranasal delivery to the brain, and further magnetic resonance imaging (MRI) was used to evaluate and confirm the transport of the positively charged CSA nanoemulsion (CSA-NE) in CNS. Furthermore, the anti-inflammatory potential of CSA peptide was evaluated using the lipopolysaccharide (LPS) model of neuroinflammation in rats. CSA-NE showed a good safety profile when tested in vitro in RPMI 2650 cells. Upon intranasal administration in rats, the nanoemulsion delivery system showed higher uptake in major regions of the brain based on changes in MRI T

Identifiants

pubmed: 30591529
pii: jpet.118.254672
doi: 10.1124/jpet.118.254672
pmc: PMC6806630
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
Cytokines 0
Emulsions 0
Fatty Acids, Omega-3 0
Lipopolysaccharides 0
Linseed Oil 8001-26-1
Cyclosporine 83HN0GTJ6D

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

843-854

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Références

Neurobiol Dis. 2004 Jun;16(1):190-201
pubmed: 15207276
J Comp Neurol. 1996 Aug 19;372(2):283-93
pubmed: 8863131
Trends Pharmacol Sci. 1998 Jan;19(1):21-6
pubmed: 9509898
J Pharm Sci. 2008 Mar;97(3):1165-78
pubmed: 17628494
Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):116-24
pubmed: 18525282
Neuropeptides. 2011 Dec;45(6):359-68
pubmed: 21592568
Cancer. 1964 Feb;17:170-5
pubmed: 14123677
Biomacromolecules. 2012 Apr 9;13(4):1074-85
pubmed: 22385328
Eur J Pharm Biopharm. 2010 Feb;74(2):290-7
pubmed: 19733661
J Pharm Sci. 2001 Nov;90(11):1729-35
pubmed: 11745730
Int J Pharm. 2016 Dec 30;515(1-2):1-10
pubmed: 27702697
Curr Opin Chem Biol. 2018 Aug;45:121-130
pubmed: 29751253
J Control Release. 2017 Apr 28;252:28-49
pubmed: 28279798
Neurosurg Focus. 2006 May 15;20(5):E9
pubmed: 16711666
Nature. 2005 Jun 2;435(7042):673-6
pubmed: 15931222
Chem Pharm Bull (Tokyo). 1995 Dec;43(12):2232-7
pubmed: 8582025
J Pharm Pharmacol. 2006 Jan;58(1):63-72
pubmed: 16393465
Drug Deliv. 2014 Mar;21(2):75-86
pubmed: 24102636
Pharmacol Biochem Behav. 2004 May;78(1):93-101
pubmed: 15159138
Cell Biol Int. 2009 Jul;33(7):739-48
pubmed: 19393753
J Control Release. 2014 Sep 28;190:637-63
pubmed: 24956489
Brain Res Brain Res Rev. 1995 Sep;21(2):195-218
pubmed: 8866675
Eur J Pharm Sci. 2005 Apr;24(5):565-73
pubmed: 15784346
Ther Deliv. 2014 Jun;5(6):709-33
pubmed: 25090283
Int J Nanomedicine. 2014 May 10;9:2241-57
pubmed: 24872687
Neuro Oncol. 2008 Apr;10(2):112-20
pubmed: 18287341
Epilepsia. 2003 Aug;44(8):995-1002
pubmed: 12887430
J Pharmacol Exp Ther. 2000 Oct;295(1):125-32
pubmed: 10991969
Psychoneuroendocrinology. 2004 Nov;29(10):1326-34
pubmed: 15288712
Mol Pharm. 2015 May 4;12(5):1523-33
pubmed: 25785492
Neuroscience. 2001;105(3):571-8
pubmed: 11516824
Toxicol Pathol. 2003 Nov-Dec;31(6):682-8
pubmed: 14585737

Auteurs

Sunita Yadav (S)

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts (S.Y., G.P., C.F., M.A.); Center for Translational Neuro-Imaging, Northeastern University, Boston, Massachusetts (P.K., C.F.); and Novartis Institute of Biomedical Research, Cambridge, Massachusetts (S.Y.).

Grishma Pawar (G)

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts (S.Y., G.P., C.F., M.A.); Center for Translational Neuro-Imaging, Northeastern University, Boston, Massachusetts (P.K., C.F.); and Novartis Institute of Biomedical Research, Cambridge, Massachusetts (S.Y.).

Praveen Kulkarni (P)

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts (S.Y., G.P., C.F., M.A.); Center for Translational Neuro-Imaging, Northeastern University, Boston, Massachusetts (P.K., C.F.); and Novartis Institute of Biomedical Research, Cambridge, Massachusetts (S.Y.).

Craig Ferris (C)

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts (S.Y., G.P., C.F., M.A.); Center for Translational Neuro-Imaging, Northeastern University, Boston, Massachusetts (P.K., C.F.); and Novartis Institute of Biomedical Research, Cambridge, Massachusetts (S.Y.).

Mansoor Amiji (M)

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts (S.Y., G.P., C.F., M.A.); Center for Translational Neuro-Imaging, Northeastern University, Boston, Massachusetts (P.K., C.F.); and Novartis Institute of Biomedical Research, Cambridge, Massachusetts (S.Y.) m.amiji@northeastern.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH